Ready-Made immune cells take on blood cancers in early trial
NCT ID NCT07518329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new cell therapy called ALA-101 for people with CD19+ non-Hodgkin lymphoma or leukemia. The therapy uses donor immune cells that are specially designed to find and attack cancer cells. The main goals are to check safety and find the best dose, with about 46 adults expected to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Epworth HealthCare
Richmond, Victoria, 3121, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Royal Adelaide Hospital
Adelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Alfred Hospital
Melbourne, Victoria, 3004, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••